24
views
0
recommends
+1 Recommend
3 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      COVID-19 Attacks the Kidney: Ultrastructural Evidence for the Presence of Virus in the Glomerular Epithelium

      research-article
      a , * , a , b
      Nephron
      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, individual patients may experience a series of different clinical settings, ranging from an asymptomatic condition to a life-threatening disease possibly amenable to combined and differential drug treatments. In most severe coronavirus disease 2019 (COVID-19) cases, uncontrolled immune response that triggers the massive proliferation of immune cells and the overproduction of cytokines appears to mediate circulatory failure and multi-organ dysfunction. Among the affected organs, the kidney is an emerging target in COVID-19 complications, and abnormal kidney function is a significant risk factor of death in severely ill patients. According to a prospective cohort study [1], 44% of COVID-19 patients had proteinuria and 27% had hematuria at hospital admission, while 5% of patients experienced acute kidney injury during in-hospital. Patients with kidney disease had a significantly higher risk for death. Autopsy studies are becoming available that point to the possibility of a direct cytopathic effect of SARS-CoV-2 on renal cells [2, 3]. In early April in Bergamo, a 93-year-old woman was admitted to the hospital with a traumatic injury. Because of her worsening dyspnea at admission and early respiratory failure, a nasopharyngeal swab was done to test SARS-CoV-2 RNA by RT-PCR, which proved positive. The respiratory failure rapidly deteriorated and the patient died 2 days after the trauma. She had a history of hypertension, diabetes, and ESRD. The analysis of kidney tissue by transmission electron microscopy taken 12-h postmortem reveals viral particles with typical features of coronavirus, indicating SARS-CoV-2 in podocytes (Figure 1). The case of this patient represents the first documented patient, in Europe, with evidence for the presence of SARS-CoV-2 in the kidney. Whether the renal involvement or other concomitant factors had a critical impact on respiratory failure and death is not clear. Very harmful consequences of injured glomerular epithelium in COVID-19 patients can be envisioned particularly in the acute setting and diabetes. They include capillary barrier dysfunction and proteinuria, hematuria, altered coagulation, and worsening of edema among multiple factors. The evaluation of kidney function should be taken into account timely in every patient at risk. Statement of Ethics In Italy, autopsy does not require informed consent from relatives. (Diagnostic assessment, National law 15 February 1961, Decree dated 10 September 1990, n.285. Approval of mortuary police regulations) Disclosure Statement The authors have no conflicts of interest to declare. Author Contributions M.A. designed the study, carried out the electron microscopy analysis and wrote the manuscript. D.R. carried out sample preparation. A.G. collected clinical data and performed the autopsy. All authors have read and approved the final version to be published.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Kidney disease is associated with in-hospital death of patients with COVID-19.

          In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m2 were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+∼3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+∼3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

            Although the respiratory and immune systems are the major targets of Coronavirus Disease 2019 (COVID-19), acute kidney injury and proteinuria have also been observed. Currently, detailed pathologic examination of kidney damage in critically ill patients with COVID-19 has been lacking. To help define this we analyzed kidney abnormalities in 26 autopsies of patients with COVID-19 by light microscopy, ultrastructural observation and immunostaining. Patients were on average 69 years (19 male and 7 female) with respiratory failure associated with multiple organ dysfunction syndrome as the cause of death. Nine of the 26 showed clinical signs of kidney injury that included increased serum creatinine and/or new-onset proteinuria. By light microscopy, diffuse proximal tubule injury with the loss of brush border, non-isometric vacuolar degeneration, and even frank necrosis was observed. Occasional hemosiderin granules and pigmented casts were identified. There were prominent erythrocyte aggregates obstructing the lumen of capillaries without platelet or fibrinoid material. Evidence of vasculitis, interstitial inflammation or hemorrhage was absent. Electron microscopic examination showed clusters of coronavirus particles with distinctive spikes in the tubular epithelium and podocytes. Furthermore, the receptor of SARS-CoV-2, ACE2 was found to be upregulated in patients with COVID-19, and immunostaining with SARS-CoV nucleoprotein antibody was positive in tubules. In addition to the direct virulence of SARS-CoV-2, factors contributing to acute kidney injury included systemic hypoxia, abnormal coagulation, and possible drug or hyperventilation-relevant rhabdomyolysis. Thus, our studies provide direct evidence of the invasion of SARSCoV-2 into kidney tissue. These findings will greatly add to the current understanding of SARS-CoV-2 infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

              Dear Editor, Tens of thousands of humans were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within a short period of time, and the infection spread quickly across China and throughout the world. Acute kidney injury (AKI) is one of the important complications of the 2019 novel coronavirus disease (COVID-19), occurring in 0.5–7% of cases and in 2.9–23% of ICU patients [1–3]. However, whether the AKI of COVID-19 is caused by a coronavirus-induced cytopathic effect or cytokine storm-induced systemic inflammatory response remains unclear. Similar to SARS-CoV infection, the spike (S) protein of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2), a host cell receptor, and the S protein is activated and cleaved by cellular transmembrane serine proteases (TMPRSSs), allowing the virus to release fusion peptides for membrane fusion [4]. Therefore, the coexpression of ACE2 and TMPRSSs is a key determinant for the entry of SARS-CoV-2 into host cells, and improves host conditions for coronavirus. To deduce the underlying mechanism of AKI during the COVID-19 outbreak, we performed single-cell RNA sequencing (scRNA-seq) analysis to identify candidate kidney host cells in the present study. First, we drafted the human kidney cell atlas with 42,589 cells from 15 normal kidney samples in three data sets for scRNA-seq analysis (Fig. S1A, Methods in the eSupplement). Subsequently, we clearly identified 19 clusters with significant differences in transcriptional activity and signature gene expression (Fig. S1A–C). Colocalization analysis of ACE2 and TMPRSS genes showed relatively high coexpression in podocytes and proximal straight tubule cells, which were identified as candidate host cells (Fig. 1a, b). The TMPRSS2 gene, as one of the most important mediators of SARS-CoV-2 enter into host cells [4], was found to be coexpressed with ACE2 in podocytes (Fig. S2A). Fig. 1 Identification of kidney host cells by scRNA-seq analysis. a Feature plots show the expression of ACE2 (red) and TMPRSS genes (blue) in kidney epithelial cells. The merged image shows the coexpression of ACE2 and TMPRSS genes, especially in proximal tubules and podocytes. b Box plots show the expression of ACE2 and the mean expression of the TMPRSS family genes in the 19 clusters of kidney cells. The expression is presented as the log2 (TP10K + 1) value Second, although there was no significant difference in the expression of TMPRSS genes, the expression of the receptor ACE2 in podocytes and proximal straight tubule cells in Occidental donors was more pronounced than that in Asian donors (Fig. S2B), suggesting that Occidental populations might be at higher risk for developing AKI in COVID-19. In addition, comparative analysis showed that the coexpression of the receptor ACE2 and TMPRSS genes in kidney cells was no less than that in the lung, oesophagus, small intestine and colon (Fig. S2C), suggesting that the kidney might also be an important target organ for SARS-CoV-2. Finally, our study clearly identified podocytes and proximal straight tubule cells as kidney host cells. Podocytes and proximal straight tubule cells play critical roles in urine filtration, reabsorption and excretion. Notably, podocytes are particularly vulnerable to viral and bacterial attacks, and podocyte injury easily induces heavy proteinuria [5]. As recent research data showed, 43.9% of SARS-CoV-2-infected patients, especially those with AKI, had proteinuria [6]. Moreover, a recent study reported the detection of SARS-CoV-2 infection in urine samples of patients with severe COVID-19 [3]. Furthermore, the entry of SARS-CoV-2 into the systemic circulation is also a key process that leads to AKI. According to published data, the length of time between the detection of SARS-CoV-2 in blood samples and AKI occurrence was approximately 7 days [1]. Based on our findings, we conclude that the cytopathic effects of SARS-CoV-2 on podocytes and proximal straight tubule cells may cause AKI in patients with COVID-19, especially in patients with SARS-CoV-2 infection in blood samples. Therefore, we need to pay more attention to the early monitoring of renal function and cautiously handle the urine of COVID-19 patients with AKI to prevent accidental infection. However, our findings were based on an analysis of normal kidney cells: the proposed mechanism of the pathophysiology of AKI during COVID-19 still needs to be validated in autopsy tissues from COVID-19 patients and functional experiments in animals and cells. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 17 kb) Supplementary material 2 (JPEG 3466 kb) Supplementary material 3 (JPEG 2693 kb) Supplementary material 4 (DOCX 21 kb)
                Bookmark

                Author and article information

                Journal
                NEF
                Nephron
                10.1159/issn.1660-8151
                Nephron
                S. Karger AG
                1660-8151
                2235-3186
                2020
                July 2020
                08 June 2020
                : 144
                : 7
                : 341-342
                Affiliations
                [_a] aDepartment of Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
                [_b] bDepartment of Laboratory Medicine, Anatomic Pathology, Azienda Ospedaliera ASST Papa Giovanni XXIII, Bergamo, Italy
                Author notes
                *Dr. Mauro Abbate, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Stezzano, 87, IT–24126 Bergamo (Italy), mauro.abbate@marionegri.it
                Article
                508430 Nephron 2020;144:341–342
                10.1159/000508430
                32512569
                820d7246-942c-405b-8e18-030e4e1b4c93
                © 2020 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 30 April 2020
                : 05 May 2020
                Page count
                Figures: 1, Pages: 2
                Categories
                Clinical Practice: Second Opinion – Medical Images from COVID-19

                Cardiovascular Medicine,Nephrology
                Cardiovascular Medicine, Nephrology

                Comments

                Comment on this article